Cullgen Acquired by Gyre Therapeutics | Healthcare M&A Deal

Gyre Therapeutics has completed the acquisition of Cullgen, a pharmacy business in CA, for $300 million. Gyre Therapeutics acquires Cullgen to expand its biopharmaceutical commercialization footprint and strengthen product development capabilities across the U.S. and China. Cullgen’s healthcare operations support the combined company’s integrated approach to drug commercialization, aligning with Gyre Therapeutics acquisitions strategy for healthcare M&A and CA acquisitions. The merger acquisition is an all-stock healthcare deals structure with private equity acquisition dynamics, creating a U.S.- and China-based fully integrated biopharmaceutical company, and closing as a completed deal.